EVOLUS, INC. Financing Cash Flow
EVOLUS, INC. (EOLS) reported Financing Cash Flow of $7.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- EVOLUS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$365.00K, a 101.77% decline year-over-year.
- EVOLUS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.62M.
- EVOLUS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $77.00K.
- EVOLUS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$1.77M.
- EVOLUS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $17.34M, a 63.43% decline from fiscal 2024.
- EVOLUS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $47.41M, a 6.21% increase from fiscal 2023.
- EVOLUS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $44.64M.
- EVOLUS, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$4.15M, a 105.68% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$365.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.25M 10-Q · filed 2026-08-05 | $7.33M derived: sum of 3 quarters · filed 2026-08-05 | $5.56M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $7.62M 10-Q · filed 2026-05-04 | $7.70M derived: sum of 2 quarters · filed 2026-05-04 | $5.92M derived: sum of 3 quarters · filed 2026-05-04 | $26.59M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$1.70M derived: sum of 2 quarters · filed 2026-03-03 | $18.97M derived: sum of 3 quarters · filed 2026-08-05 | $17.34M 10-K · filed 2026-03-03 | |
| 2025-09-30 | -$1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $18.89M derived: sum of 2 quarters · filed 2026-08-05 | $17.26M 10-Q · filed 2025-11-05 | $15.95M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $20.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $19.03M 10-Q · filed 2026-08-05 | $17.72M derived: sum of 3 quarters · filed 2026-08-05 | $16.30M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$1.63M 10-Q · filed 2026-05-04 | -$2.94M derived: sum of 2 quarters · filed 2026-05-04 | -$4.36M derived: sum of 3 quarters · filed 2026-05-04 | $121.00K derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$2.73M derived: sum of 2 quarters · filed 2026-03-03 | $1.75M derived: sum of 3 quarters · filed 2026-03-03 | $47.41M 10-K · filed 2026-03-03 | |
| 2024-09-30 | -$1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.06M derived: sum of 2 quarters · filed 2025-11-05 | $48.73M 10-Q · filed 2025-11-05 | $72.25M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-06-30 | $4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $50.14M 10-Q · filed 2025-08-05 | $73.67M derived: sum of 3 quarters · filed 2026-03-03 | $72.25M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-03-31 | $45.66M 10-Q · filed 2025-05-07 | $69.18M derived: sum of 2 quarters · filed 2026-03-03 | $67.77M derived: sum of 3 quarters · filed 2026-03-03 | $91.58M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2023-12-31 | $23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $22.10M derived: sum of 2 quarters · filed 2026-03-03 | $45.92M derived: sum of 3 quarters · filed 2026-03-03 | $44.64M 10-K · filed 2026-03-03 | |
| 2023-09-30 | -$1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $22.40M derived: sum of 2 quarters · filed 2024-11-06 | $21.12M 10-Q · filed 2024-11-06 | $19.60M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-06-30 | $23.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $22.54M 10-Q · filed 2024-07-31 | $21.02M derived: sum of 3 quarters · filed 2025-03-04 | $20.26M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-03-31 | -$1.28M 10-Q · filed 2024-05-07 | -$2.80M derived: sum of 2 quarters · filed 2025-03-04 | -$3.56M derived: sum of 3 quarters · filed 2025-03-04 | -$4.41M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2022-12-31 | -$1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$2.27M derived: sum of 2 quarters · filed 2025-03-04 | -$3.12M derived: sum of 3 quarters · filed 2025-03-04 | -$4.15M 10-K · filed 2025-03-04 | |
| 2022-09-30 | -$759.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$1.61M derived: sum of 2 quarters · filed 2023-11-07 | -$2.63M 10-Q · filed 2023-11-07 | $45.26M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$849.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$1.87M 10-Q · filed 2023-08-02 | $46.02M derived: sum of 3 quarters · filed 2023-08-02 | $54.19M derived: sum of 4 quarters · filed 2023-08-02 | |
| 2022-03-31 | -$1.02M 10-Q · filed 2023-05-09 | $46.87M derived: sum of 2 quarters · filed 2023-05-09 | $55.03M derived: sum of 3 quarters · filed 2023-05-09 | $148.87M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $47.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $56.06M derived: sum of 2 quarters · filed 2023-03-08 | $149.89M derived: sum of 3 quarters · filed 2023-03-08 | $73.05M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $8.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $102.00M derived: sum of 2 quarters · filed 2022-11-08 | $25.16M 10-Q · filed 2022-11-08 | $25.16M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $93.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $17.00M 10-Q · filed 2022-08-02 | $17.00M derived: sum of 3 quarters · filed 2022-08-02 | $56.76M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | -$76.84M 10-Q · filed 2022-05-10 | -$76.84M derived: sum of 2 quarters · filed 2022-05-10 | -$37.07M derived: sum of 3 quarters · filed 2022-05-10 | -$37.39M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $39.77M derived: sum of 2 quarters · filed 2022-03-03 | $39.45M derived: sum of 3 quarters · filed 2022-03-03 | $38.35M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $39.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $39.45M derived: sum of 2 quarters · filed 2021-11-02 | $38.35M 10-Q · filed 2021-11-02 | $111.07M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | -$315.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$1.42M 10-Q · filed 2021-08-04 | $71.30M derived: sum of 3 quarters · filed 2021-08-04 | $70.84M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | -$1.10M 10-Q · filed 2021-05-12 | $71.62M derived: sum of 2 quarters · filed 2021-05-12 | $71.16M derived: sum of 3 quarters · filed 2021-05-12 | $72.01M derived: sum of 4 quarters · filed 2021-05-12 | |
| 2019-12-31 | $72.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $72.26M derived: sum of 2 quarters · filed 2021-03-25 | $73.12M derived: sum of 3 quarters · filed 2021-03-25 | $133.55M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$460.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $393.00K derived: sum of 2 quarters · filed 2020-10-29 | $60.82M 10-Q · filed 2020-10-29 | $60.82M derived: sum of 4 quarters · filed 2020-10-29 | |
| 2019-06-30 | $853.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $61.28M 10-Q · filed 2020-08-10 | $61.28M derived: sum of 3 quarters · filed 2020-08-10 | $128.66M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $60.43M 10-Q · filed 2020-05-11 | $60.43M derived: sum of 2 quarters · filed 2020-05-11 | $127.81M derived: sum of 3 quarters · filed 2020-05-11 | $127.50M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $67.38M derived: sum of 2 quarters · filed 2020-02-25 | $67.07M derived: sum of 3 quarters · filed 2020-02-25 | $118.84M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $67.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $67.07M derived: sum of 2 quarters · filed 2019-11-04 | $118.84M 10-Q · filed 2019-11-04 | $119.84M derived: sum of 4 quarters · filed 2019-11-04 | |
| 2018-06-30 | -$312.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $51.46M 10-Q · filed 2019-08-12 | $51.46M 10-Q · filed 2018-08-02 | $52.46M derived: sum of 3 quarters · filed 2019-08-12 | $55.89M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $51.77M 10-Q · filed 2019-05-01 | $52.77M derived: sum of 2 quarters · filed 2019-05-01 | $56.20M derived: sum of 3 quarters · filed 2019-05-01 | $59.41M derived: sum of 4 quarters · filed 2019-05-01 | |
| 2017-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | $4.43M derived: sum of 2 quarters · filed 2019-03-20 | $7.64M derived: sum of 3 quarters · filed 2019-03-20 | $13.04M 10-K · filed 2019-03-20 | |
| 2017-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $6.64M derived: sum of 2 quarters · filed 2018-11-05 | $12.04M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $8.61M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | $5.39M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |